Literature DB >> 30361901

Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.

Marilena Argyropoulou1, Aristidis S Veskoukis1, Pagona-Maria Karanatsiou1, Aikaterini Manolakelli1, Ifigenia Kostoglou-Athanassiou2, George Vilaras3, Andreas Karameris3, Kalliopi Liadaki4.   

Abstract

Thyroid cancer is a common endocrine malignancy and displays a variety of histological patterns ranging from adenoma to malignant tumors. Molecular diagnostics have given significant insights into the genetic basis of thyroid tumorigenesis, known to be linked with signaling pathways affected by oxidative stress. We report for the first time a genotype study of TERT promoter combined with BRAF and RAS mutations in Papillary Thyroid Cancer (PTC) cases in the Greek population. Polymerase Chain Reaction and sequencing were used to identify TERT promoter (C228T, C250T, CC243-243TT) mutations, the BRAF (T1799A) mutation and mutations in codons 12, 13, 61 of the HRAS, KRAS and NRAS genes. The most common C228T TERT promoter mutation was identified in 2 PTC cases co-existing with the BRAF mutation. The BRAF T1799A mutation was detected in 10 PTC cases, while two different NRAS mutations in codon 61 (C181A and A182G) were found in 2 PTC cases. These mutations occur in a mutually exclusive manner. Our results indicate that despite the low frequencies, the study of the specific mutations should be encouraged because they are indicative of aggressive forms of thyroid cancer of the papillary histotype in this patient cohort, thus providing insights towards their therapeutic management.

Entities:  

Keywords:  BRAF; Mutations; Papillary thyroid cancer; RAS; TERT

Year:  2018        PMID: 30361901     DOI: 10.1007/s12253-018-0497-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  38 in total

1.  Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.

Authors:  Hans-Juergen Schulten; Sherine Salama; Alaa Al-Ahmadi; Zuhoor Al-Mansouri; Zeenat Mirza; Khalid Al-Ghamdi; Osman Abdel Al-Hamour; Etimad Huwait; Mamdooh Gari; Mohammad Hussain Al-Qahtani; Jaudah Al-Maghrabi
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

2.  NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas.

Authors:  Naïma Azouzi; Jérémy Cailloux; Juliana M Cazarin; Jeffrey A Knauf; Jennifer Cracchiolo; Abir Al Ghuzlan; Dana Hartl; Michel Polak; Aurore Carré; Mohammed El Mzibri; Abdelkarim Filali-Maltouf; Abderrahmane Al Bouzidi; Martin Schlumberger; James A Fagin; Rabii Ameziane-El-Hassani; Corinne Dupuy
Journal:  Antioxid Redox Signal       Date:  2016-08-22       Impact factor: 8.401

3.  TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

Authors:  Xiaoli Liu; Shen Qu; Rengyun Liu; Chunjun Sheng; Xiaoguang Shi; Guangwu Zhu; Avaniyapuram Kannan Murugan; Haixia Guan; Hongyu Yu; Yangang Wang; Hui Sun; Zhongyan Shan; Weiping Teng; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2014-03-11       Impact factor: 5.958

4.  Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

Authors:  Claudio Carta; Sonia Moretti; Lucia Passeri; Flavia Barbi; Nicola Avenia; Antonio Cavaliere; Massimo Monacelli; Antonio Macchiarulo; Fausto Santeusanio; Marco Tartaglia; Efisio Puxeddu
Journal:  Clin Endocrinol (Oxf)       Date:  2006-01       Impact factor: 3.478

5.  BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.

Authors:  Nikolaos Goutas; Dimitrios Vlachodimitropoulos; Myrto Bouka; Andreas C Lazaris; George Nasioulas; Maria Gazouli
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

6.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  Papillary carcinoma of the thyroid. A discussion of its several morphologic expressions, with particular emphasis on the follicular variant.

Authors:  J Rosaí; G Zampi; M L Carcangiu
Journal:  Am J Surg Pathol       Date:  1983-12       Impact factor: 6.394

8.  BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Authors:  F Frasca; C Nucera; G Pellegriti; P Gangemi; M Attard; M Stella; M Loda; V Vella; C Giordano; F Trimarchi; E Mazzon; A Belfiore; R Vigneri
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

Review 9.  Progress in molecular-based management of differentiated thyroid cancer.

Authors:  Mingzhao Xing; Bryan R Haugen; Martin Schlumberger
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

10.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

View more
  7 in total

1.  The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis.

Authors:  Ling Zhao; Lin Wang; Xiaomeng Jia; Xiaodong Hu; Ping Pang; Sitong Zhao; Yajing Wang; Jing Wang; Yingshi Zhang; Zhaohui Lyu
Journal:  Front Oncol       Date:  2020-11-03       Impact factor: 6.244

2.  A diagnostic and predictive lncRNA lnc-MPEG1-1 promotes the proliferation and metastasis of papillary thyroid cancer cells by occupying miR-766-5p.

Authors:  Chan Huang; Xuan Su; Da-Lei Zhou; Bo-Heng Xu; Qing Liu; Xiao Zhang; Tao Tang; Xin-Hua Yang; Zu-Lu Ye; Cai-Yun He
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-31       Impact factor: 10.183

3.  Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jingxin Mao; Qinghai Zhang; Haiyan Zhang; Ke Zheng; Rui Wang; Guoze Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

Review 4.  Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.

Authors:  Kelly L Harris; Meagan B Myers; Karen L McKim; Rosalie K Elespuru; Barbara L Parsons
Journal:  Environ Mol Mutagen       Date:  2019-10-06       Impact factor: 3.216

5.  Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.

Authors:  Jing Yang; Yanping Gong; Shuping Yan; Hui Chen; Siqin Qin; Rixiang Gong
Journal:  Endocrine       Date:  2019-10-26       Impact factor: 3.633

6.  Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital.

Authors:  Adhitya Bayu Perdana; Rizky Ifandriani Putri; Rachmawati Rachmawati; Bob Andinata; Bayu Brahma
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01

Review 7.  Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.

Authors:  Xiaotian Yuan; Tiantian Liu; Dawei Xu
Journal:  Ann Transl Med       Date:  2020-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.